

A Modular Safety System for an Insulin Dose Recommender: a Feasibility Study

Chengyuan Liu, PhD^{1§}, Parizad Avari, MRCP^{2§}, Yenny Leal, PhD³, Marzena Wos, MD³, Kumuthine Sivasithamparam, BSc², Pantelis Georgiou, PhD¹, Monika Reddy, PhD², José Manuel Fernández-Real, PhD³, Clare Martin, PhD⁴, Mercedes Fernández-Balsells, PhD³, Nick Oliver, FRCP², Pau Herrero, PhD¹

§: Both authors contributed equally to this work

Author Affiliations: ¹ Centre for Bio-Inspired Technology, Department of Electrical and Electronic engineering, Imperial College London, London, UK; ² Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Imperial College, London, UK.; ³ Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain; ⁴ Department of Computing and Communication Technologies, Oxford Brookes University, Oxford UK.

Chengyuan Liu, Pantelis Georgiou and Pau Herrero: Centre for Bio-inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, U.K., +44 (0)2075940840, {chengyuan.liu12, pantelis, pherrero }@imperial.ac.uk

Parizad Avari, Kumuthine Sivasithamparam, Nick Oliver: Hammersmith Hospital, Imperial College Healthcare NHS Trust, Fulham Palace Road, London, UK, W6 8RF, {p.avar, kumuthine.sivasithamparam14, m.reddy, nick.oliver}@imperial.ac.uk

Yenny Leal, Marzena Wos, José Manuel Fernández-Real, Mercedes Fernández-Balsells: Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Salt, Girona, Spain, 17190, {yleal, mawos, mfernandez, [jmfreal](mailto:jmfreal@idibgi.org)}@idibgi.org

Clare Martin: Department of Computing and Communication Technologies, Oxford Brookes University, Oxford UK, cemartin@brookes.ac.uk

Abbreviations: T1D (Type 1 Diabetes); MDI (multiple daily injections); CGM (Continuous glucose monitoring); CSII (Continuous Subcutaneous Insulin Infusion); Ra (rate of glucose appearance); PLGBI

(predictive low glucose basal insulin suspension); R2R (run-to-run) ; carbohydrate sensitivity factor (CSF); DBIC (Dynamic Bolus Insulin Constraint); ICR (carbohydrate-to-insulin ratio); ISF (insulin sensitivity factor); IOB (insulin-on-board); CHO (carbohydrates); G (glucose); CBR (case-based reasoning); DKA (diabetic ketoacidosis); IQR (interquartile range).

Key Words: type 1 diabetes; insulin delivery; decision support; safety; run-to-run control.

Corresponding Author: Pau Herrero, Ph.D.; Centre for Bio-Inspired Technology, Department of Electrical and Electronic Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, U.K. pherrero@imperial.ac.uk

Figures and table count: 7 figures, 2 tables.

Funding Source: This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement 689810.

Conflict-of-Interest Disclosure: None

Abstract

Background: Delivering insulin in type 1 diabetes is a challenging, and potentially risky, activity; hence the importance of including safety measures as part of any insulin dosing or recommender system. This work presents and clinically evaluates a modular safety system that is part of an intelligent insulin dose recommender platform developed within the EU-funded PEPPER project.

Methods: The proposed safety system is composed of four modules which use a novel glucose forecasting algorithm. These modules are: predictive glucose alerts and alarms; a predictive low-glucose basal insulin suspension module; an advanced rescue carbohydrate recommender for resolving hypoglycaemia; and a personalised safety constraint applied to insulin recommendations. The technical feasibility of the proposed safety system was evaluated in a pilot study including eight adult subjects with type 1 diabetes on multiple daily injections over a duration of six weeks. Glycaemic control and safety system functioning were

compared between the two-weeks run-in period and the end-point at eight weeks. A standard insulin bolus calculator was employed to recommend insulin doses.

Results: Overall, glycaemic control improved over the evaluated period. In particular, percentage time in the hypoglycaemia range ($<3.0\text{mmol/l}$) significantly decreased from 0.82 (0.05-4.79) % at run-in to 0.33 (0.00-0.93) % at endpoint ($p=0.02$). This was associated with a significant increase in percentage time in target range ($3.9\text{-}10.0\text{mmol/l}$) from 52.8 (38.3-61.5) % to 61.3 (47.5-71.7) % ($p=0.03$). There was also a reduction in number of carbohydrate recommendations.

Conclusion: A safety system for an insulin dose recommender has been proven to be a viable solution to reduce the number of adverse events associated to glucose control in type 1 diabetes.

1 Introduction

Type 1 diabetes (T1D) is a long-term condition characterized by a loss of insulin secretion by the pancreatic β cells [1]. Currently, people with T1D measure capillary blood glucose several times daily and administer exogenous insulin via multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Continuous glucose monitoring (CGM) technology [2] has opened the door to more advanced technologies to control glucose levels, such as sensor-augmented insulin pumps with low-glucose insulin suspend [3], the artificial pancreas [4], and decision support systems for insulin dosing [5]. However, although these advanced delivery systems have been associated with improvements in glycaemic control, they are not able to wholly eliminate hypo- and hyperglycaemia and introduce the additional risk of malfunctioning of one of their components [6][7]. Therefore, there is a clear need to include a safety system to minimise such adverse events.

Current real-time CGM systems incorporate glucose alarms, and more recently predictive glucose alerts, that notify the user of hypo- and hyperglycaemia events [8]. In addition, existing sensor-augmented pumps incorporate a predictive low-glucose insulin suspension system (Medtronic MiniMed 640G with SmartGuard; Tandem t:slim X2 pump with Basal-IQ) to reduce nocturnal hypoglycaemia [3]. Various automated strategies have been proposed to recommend carbohydrate doses to avoid or revert hypoglycaemia [9,10]. Finally, different methods have been proposed to minimize the risk of adverse events due to CGM and pump failures [11].

In this work, we present a modular safety system developed within the framework of the EU-funded PEPPER (Patient Empowerment through Predictive PERsonalised decision support) project [12]. PEPPER, is a personalised decision support system for T1D self-management, which includes an insulin bolus recommender based on the artificial intelligence technique of case-based reasoning [13,14] and a safety system.

PEPPER offers a dual architecture to cater for both MDI or CSII treatment, the latter via the Cellnovo patch-pump (Cellnovo Ltd., UK; Figure 1). In both cases, the user wears real-time CGM (Dexcom G5, CA, US) which communicates to the hand-held device via xDrip+ [15]. An activity monitor (MiBand 1s,

Xiaomi, China) is included to determine physical activity. Additional data such as food intake, alcohol consumption, stress, hormonal cycles are input through the user interface (Figure 2) of the hand-held unit (smartphone or Cellnovo handset). The hand-held unit remotely communicates to a secure web server where all collected data is uploaded and stored. Finally, a web-based user interface enables the clinical team to monitor the functioning of the system (PEPPER clinical platform). Although the presented safety system has been developed to integrate within the PEPPER platform, it can easily be adapted to other insulin dosing systems (e.g. artificial pancreas).




Figure 1. Left) PEPPER system MDI and CSII architectures and Right) PEPPER system components




Figure 2. PEPPER graphical user interface corresponding to the smartphone version. Blue square displays an estimate of the active insulin bolus; yellow circle shows an estimate of the remaining carbohydrates on-board; pink circle displays the blood glucose level coming from the CGM; The upper graph shows the CGM measurements in dotted (pink line) and the 30-minute forecasted glucose values (dotted green line); the remaining graphs display the injected insulin boluses, the ingested carbohydrates, and the step counts, respectively. ‘Get bolus advice’ button triggers an insulin dose recommendation that is displayed to the user.

2 Methods

The PEPPER safety system comprises of four modules: the first module consists of predictive glucose threshold crossing alerts and standard glucose threshold crossing alarms. The second module is designed for insulin pump users and automatically suspends basal insulin delivery when predicted glucose levels are low. A third module recommends an individualized carbohydrate to harmlessly return glucose to safe levels. Finally, the fourth module, referred to as dynamic bolus insulin constraint, restricts the amount of insulin

that can be safely recommended to the user (Figure 3). Details of these four modules are given in the following sections.




Figure 3. Block diagram of the safety system with the four modules, and corresponding inputs and outputs.

2.1 Module 1: Glucose Alerts and Alarms Module

The glucose alerts and alarms module consists of two predictive alerts using a 30-minute glucose forecasting algorithm (Appendix A) to notify the user before reaching predefined high and low glucose thresholds. In addition, standard glucose alarms notify the user when thresholds measured by the CGM are exceeded. The user is able to choose the thresholds for when alerts are triggered, while the alarm thresholds are hard-coded and cannot be modified (3.9mmol/l for hypoglycemia and 16.6mmol/l for hyperglycemia). To prevent alarm fatigue, once an alert, or alarm, has been snoozed by the user, another alert, or alarm, cannot be triggered until a predefined time interval of 30minutes has elapsed. In addition, alerts can be muted, but alarms cannot for safety reasons. Finally, if the user does not address a hypoglycaemia alarm before a predefined time interval of 30minutes, an SMS message containing the type of alarm (i.e. hypoglycemia or hyperglycemia) and the time it was triggered, is sent to a designated carer. The system keeps sending messages every 30minutes until the alarm is snoozed on the handheld unit. Figure 4 shows a real example of functioning of the predictive glucose alerts and alarms module.

2.2 Module 2: Predictive Low-glucose Basal Insulin Suspend Module

The predictive low glucose basal insulin suspension (PLGBI) module aims at minimising the incidence and severity of hypoglycemia by suspending, or partially suspending, basal insulin delivery when predicted glucose levels are low. Basal insulin delivery is reduced by 50% (partial suspension) if the 30-minute forecasted glucose value (Appendix A) falls below a predefined threshold (Threshold 1). Insulin delivery is fully suspended when glucose falls below a second predefined threshold (Threshold 2), which is lower than Threshold 1. Due to a technical limitation, full suspension of the pump is not possible and is set at a rate of 0.01 U/h, which is negligible for most people with T1D. This was done because it was the only way to make the pump resume without manual intervention. While suspended, insulin is resumed to 50% when forecasted glucose is above Threshold 2 and is fully resumed when forecasted above Threshold 1. A total suspension time limit of 90minutes prevents excessive insulin deficiency and rebound hyperglycaemia. After this time limit, insulin is resumed to 50% for up to 30minutes. Basal insulin delivery can be resumed at any time by the user. For this clinical trial, Threshold 1 was set to 4.5mmol/l and Threshold 2 to 3.9mmol/l. Figure 4 shows the functioning of the PLGBI module over a real clinical scenario. Note, low-glucose suspend was not applied since the displayed data corresponds to an MDI participant.

2.3 Module 3: Adaptive Carbohydrate Recommender

If neither glucose alerts/alarms module nor the predictive PLGBI module are enough to prevent hypoglycemia, the adaptive carbohydrate recommender module recommends a rescue dose of oral carbohydrates with the aim of reverting hypoglycaemia and minimizing rebound hyperglycemia. In particular, if the CGM glucose measurement falls below a pre-defined hypoglycaemic threshold (2.8mmol/l), the carbohydrate recommendation (CHO_{rescue}) is calculated as follows

$$CHO_{rescue} = \left\lceil \frac{G_{setpoint} - G_{forecast}}{CSF} - COB \right\rceil, \quad (1)$$

where $G_{setpoint}$ is a predefined setpoint where glucose concentration is aimed to be after ingesting the rescue carbohydrates (6.7mmol/l), $G_{forecast}$ is the 30-minute predicted glucose concentration (Appendix A), CSF

is the carbohydrate sensitivity factor defined as the glucose concentration increase (mmol/l) per 1 gram of carbohydrates, and COB are the estimated rescue carbohydrates-on-board, which are as follows

$$COB(t) = CHO_{rescue} - \int_{t_{meal}}^t R_a(\tau) dt, \quad (2)$$

where R_a is the rate of glucose appearance from previously ingested rescue carbohydrates and estimated with the model proposed by Dalla Man et al. [16], t_{meal} is the time the previous rescue's dose was ingested and t is the current time.

The CSF is initialized with the guidelines provided by Walsh et al. [17] based on body weight. If such initialization is not accurate, CSF is updated using a run-to-run (R2R) control algorithm [18] that adapts such parameter to effectively minimize both hypoglycaemia and rebound hyperglycaemia. The R2R control law is defined as follows

$$CSF_{k+1} = CSF_k - K_1 |Th_{hypo} - G_{min}| + K_2 |G_{max} - Th_{hyper}|, \quad (3)$$

where Th_{hypo} and Th_{hyper} are predefined hypoglycaemia and hyperglycaemia thresholds, G_{min} and G_{max} are the minimum and maximum glucose values within the time window that spans from 20 minutes to one hour after the rescue dose intake. Finally, K_1 and K_2 are tuning gains which are subject specific and correlated to CSF. In this work, $Th_{hypo}=4.4\text{mmol/l}$, $Th_{hyper}=8.3\text{mmol/l}$, $K_1=0.05$ and $K_2=0.01$ were employed. Figure 4 shows on a real scenario the recommendation of a carbohydrate dose.




Figure 4. Clinical scenario showing the functioning of the PEPPER safety system. Dotted blue line corresponds to the CGM measurements and the dotted red line to the forecasted glucose values.

Horizontal dashed lines are the glucose thresholds for the predictive alerts (4.4mmol/l) and for the alarms (3.9mmol/l). Dark-blue bars and red bars are the meals and insulin boluses respectively. Solid magenta line represents the percentage of basal delivery as a result of the low-glucose insulin suspend module.

Cyan bars and black bar correspond to the alerts and alarms respectively. Green bars represent the carbohydrate recommendations.

2.4 Module 4: Dynamic Bolus Insulin Constraint

The Dynamic Bolus Insulin Constraint (DBIC) module aims to eliminate potentially dangerous insulin boluses being recommended to the user, which could induce severe hypo- or hyperglycaemia. DBIC represents an additional safety layer to the ones already set in place by the CBR-based insulin recommender [13,14].

DBIC is based on an insulin bolus calculator [19], which is expressed by

$$Bolus = \frac{CHO}{ICR} + \frac{G - G_T}{ISF} - IOB, \quad (4)$$

where CHO (gram) is the amount of estimated carbohydrate, G (mmol/l) is the blood glucose measurement, G_T (mmol/l) is the blood glucose target, ICR (g/U) and ISF (mmol/l/U) are two patient-specific parameters namely the carbohydrate-to-insulin ratio and the insulin sensitivity factor, and IOB (U) is the insulin-on-board, which can be calculated using a linear decay expressed as

$$IOB = B_p \left(1 - \frac{T_{int}}{T_{act}}\right), \quad (5)$$

where B_p the previously administered insulin bolus, T_{int} is the elapsed time since the last administered insulin bolus and T_{act} is the insulin action time, which is subject dependent.

The inherent uncertainty of the bolus calculator parameters and inputs are bounded by means of numerical intervals $[a, b]$, where a and b are real numbers and $a \leq b$. For instance, assuming a 15% misestimation error in carbohydrate counting, a meal containing 100grams of carbohydrates is represented by the interval $CHO=[85, 115]$ grams. Interval arithmetic [20] is then used to propagate such uncertainty to the output; hence the resulting bolus insulin dose is also an interval. As a matter of example, assume the uncertainty on the insulin bolus calculator parameters and inputs to be: ICR ($\pm 30\%$), ISF ($\pm 30\%$), T_{act} (± 30 min), G ($\pm 9\%$), and CHO ($\pm 15\%$). Also, assume the scenario where $G=8.3$ mmol/l, $G_T=6.7$ mmol/l, $CHO=70$ grams, $ICR=10$ gram/U, $ISF=2.2$ mmol/l/U and $IOB=0$ U. Then, the resulting bolus insulin interval is $Bolus = [4.8, 13.0]$ U. Hence, if the recommended insulin dose is outside such interval, it is saturated to the corresponding lower or upper bound. Finally, the resulting value is displayed on the user when the advice button is pressed.

To summarize, the interval-based standard formula above is used to calculate the bound constraints, whilst the CBR-based insulin recommender is used to calculate the bolus in real time. It is important to remark that, in this work, the CBR-based insulin recommender was not active during the feasibility trials and insulin bolus recommendations were based on a standard bolus calculator, which corresponds to the mid-point of the bound constraints.

2.5 Clinical evaluation

To analyse the PEPPER system, the design of the study is completed over three phases. Phase 1 assesses the safety and feasibility of the PEPPER safety system (without the CBR-based insulin recommender). Phase 2 evaluates the overall PEPPER system (integrated with the CBR-based insulin recommender). Phase 3 is a randomised open-label cross-over trial comparing the complete PEPPER system to a standard bolus calculator.

In this work, preliminary data from participants on MDI is presented only. Hence, Module 3 (PLGBI) is not evaluated since it is exclusive to pump users. In addition, as the PEPPER Insulin Recommender is not being evaluated, Module 4 (Dynamic Bolus Insulin Constraint) is not properly evaluated and, instead, is used as standard meal-insulin bolus calculator.

2.5.1 Study Design and Participants

Phase 1 is a non-randomised, open label study. Ethics approval was obtained from the relevant Ethics Committees at each of the sites. Adult participants with T1D for >1 year and on MDI treatment for >6 months. All participants had to have completed a structured education programme and be competent at carbohydrate counting.

Exclusion criteria included: an episode of diabetic ketoacidosis (DKA) or severe hypoglycaemia requiring third-party assistance (within the last 6 months), use of regular paracetamol, pregnancy, breastfeeding, active malignancy or endocrinopathy, abnormal renal function or liver cirrhosis, or macrovascular complications in the past year. All participants gave informed written consent.

2.5.2 Procedures

At study enrolment, participants gave a full medical history and underwent a physical examination. Random venous bloods, including HbA1c, were taken. A urine sample was taken to measure albumin/creatinine ratio. The Gold Score questionnaire was completed, which is a subjective rating given by the participant on

a scale from 1 (always) to 7 (never) in response to the question “Do you know when your hypos are commencing?”.

Participants meeting the inclusion criteria were provided the PEPPER system. For Phase 1, the PEPPER CBR-based insulin recommender was disabled and a standard bolus calculator was used. Participants were instructed to use the equipment according to its license.

The study comprised of four visits over 8 weeks. There was a two-week initial run-in period using the PEPPER system with the safety system disabled but with xDrip+ glucose alarms activated. A second visit was scheduled at the end of Week 2, and the PEPPER safety system was activated on the handset. A third visit was scheduled at the end of Week 4 and a final visit at the end of the study.

At each visit, CGM data were reviewed by the researcher with the participant and changes were made to the basal insulin/ISF/ICR as required. Verbal feedback from participants was obtained regarding any technical issues encountered. Technical issues identified in the assessment were dealt with system redevelopment. At visit 4, the PEPPER system was switched off and returned.

2.5.3 Outcomes

The primary outcome was percentage (%) time in hypoglycaemia (<3.9mmol/l) from baseline to endpoint. Secondary outcomes included low and high glucose alarms, carbohydrate recommendations, low glucose suspend (CSII users only), technical faults of the PEPPER system. Secondary outcomes regarding glycaemic control include: %time in target (3.9-10mmol/l), %time in hyperglycaemia (>10mmol/l) and lower thresholds of hypoglycaemia (<3.3mmol/l and 3.0mmol/l).

2.5.4 Statistical Analysis

All glycaemic outcomes from baseline (weeks 1 and 2) were compared with endpoint (weeks 7 and 8). Non-normally distributed data were analysed with the Wilcoxon matched-pairs signed-rank test. For data

analysed on a fortnightly basis, an analysis of variance (ANOVA) was used. All outcomes are reported as median (interquartile range [IQR]), unless stated otherwise. P-values <0.05 were considered statistically significant.

The glycaemia and safety system data for each participant were stored on the PEPPER Server Application (PSA), which were exported as a test file and run on MATLAB script to calculate the primary and secondary outcomes for each week of the study. A formal power calculation was not performed for Phase 1 pilot studies assessing feasibility and safety of new technology.

3 Results

Eight participants were recruited at two sites, namely Imperial College Healthcare NHS Trust, London, UK (n=4) and Hospital Universitari de Girona Dr Josep Trueta, Spain (n=4). Participants (3 men and 5 female) had a median (IQR) age of 37.5 (31.8-53.5) years, duration of diabetes 22.5 (18.0-26.5) years, BMI 23.8 (23.2-27.5) and HbA1c 63.0 (57.4-66.1) mmol/mol (table 1). All participants had good awareness of hypoglycaemia with a gold score of 2.0 (1.75-2.25).

Six participants completed the 8-week Phase 1 study. The reasons for the two participants not included in the final analysis were due to one drop out for personal commitments and one participant having handset issues.

3.1.1 Glycaemic Outcomes

A comparison of glucose outcomes was derived from the run-in CGM data (baseline weeks 1 and 2) and compared with endpoint (weeks 7 and 8). Median %time<3.0mmol/l fell from 0.8% during run-in (weeks 1 and 2) to 0.3% at end-point (weeks 7 and 8; p=0.02; Table 1; Figure 5). For the primary outcome comparison (%time <3.9mmol/l) and %time <3.3mmol/l, no significant difference was observed between the two groups.

Percentage time in target (3.9-10mmol/l) significantly increased with use of the PEPPER safety system compared to standard system ($p<0.05$). No significant difference for time in hyperglycaemia ($>10\text{mmol/l}$) was observed.

No adverse incidents of DKA or severe hypoglycaemia requiring third-party assistance occurred during the eight weeks. One participant was admitted to hospital due to hyperglycaemia precipitated by a mild lower respiratory tract infection.

Table 1: Median percentage(%) time (and IQR) spent within various glucose ranges at baselines (weeks 1 and 2) and endpoint (weeks 7 and 8). Reduction of % time in hypoglycaemia $<3.0\text{mmol/L}$, was observed in all 6 individuals. For % time in hypoglycaemia $<3.3\text{mmol/L}$, reduction was observed in 5 out of 6 individuals.

	Run-in (n=6) Weeks 1 and 2	Endpoint (n=6) Weeks 7 and 8	P-value
% time in hypoglycaemia			
$<3.9\text{mmol/l}$	3.6 (1.5-6.3)	2.7 (0.9-7.2)	0.15
$<3.3\text{mmol/l}$	1.8 (0.6-5.6)	0.7 (0.0-1.5)	0.05
$<3.0\text{mmol/l}$	0.8 (0.0-4.7)	0.3 (0.0-0.9)	0.02
% time in target			
3.9-10mmol/l	52.8 (38.3-61.5)	61.3 (47.5-71.7)	0.02
% time in hyperglycaemia			
$>10\text{mmol/l}$	44.3 (37.3-57.8)	33.8 (27.5-49.2)	0.09




Figure 5. Box plot graphs showing the change in glycaemic outcomes on a fortnightly basis over the eight-week study. (a) Change in percentage time in hypoglycaemia (<3.0mmol/l), (b) change in percentage time in target (3.9-10.0mmol/l), (c) change in percentage time in hyperglycaemia (>10mmol/l). * ANOVA $p < 0.05$

3.1.2 Safety System Outcomes

The total incidence of PEPPER safety system outcomes (i.e. glucose alerts, alarms and carbohydrate recommendations) between run-in and end-point are shown in Table 2. It is important to remark that during the run-in period, the safety system was disabled but still running in the background, hence the glucose alerts, alarms, and carbohydrate recommendations were blinded to the user. Nevertheless, the user had the xDrip+ glucose alarms activated with the same thresholds as with the PEPPER safety system. This makes the comparison of glucose alerts and carbohydrate recommendations not completely fair because the user was not able to react to these events during the run-in period. However, we consider that these results are still informative of the improvement on glycaemic control.

The total incidence of glucose alerts significantly reduced by approximately one-third at endpoint compared to run-in ($p<0.05$; Table 2), but no difference was observed when categorised into type of alert (i.e. hypoglycaemia/ hyperglycaemia). Note that the observed difference in the incidence of glucose alerts might be due to the users changing the glucose alerts thresholds during the trial. Incidence of glucose alarms did not change.

All carbohydrate recommendations were considered, regardless of whether the user acted upon the advice recommended by the PEPPER system. The median total number of carbohydrate recommendations reduced to zero by endpoint, which correlates with the reduction in hypoglycaemia $<3.0\text{mmol/l}$ observed.

Table 2. Safety system outcomes comparing run-in and endpoint. Data expressed as median (IQR).

	Run-in (n=6) Weeks 1 and 2	Endpoint (n=6) Weeks 7 and 8	P-value
Incidence of all glucose alerts	31.5 (24.5-38.8)	20.0 (12.8-25.3)	0.03
For hypoglycaemia	7.0 (3.7-12.0)	3.5 (2.0-14.0)	0.36
For hyperglycaemia	18.0 (10.0-26.0)	10.5 (6.7-14.0)	0.06
Incidence of all glucose alarms	15.0 (7.2-23.5)	12.0 (8.2-20.8)	0.18
For hypoglycaemia	5.5 (4.0-9.3)	5.5 (3.0-8.2)	0.41
For hyperglycaemia	4.0 (0.7-6.2)	3.5 (1.5-6.0)	0.33
Incidence of all carbohydrate recommendations	4.5 (1.0-88.3)	0.0 (0.0-25.3)	0.18

Data loss was observed for periods of time between the CGM device and handset. Approximately 49.6% of missed signals were observed in the initial run-in period and was reduced to 19.1% by end-point.

4 Discussion

This feasibility study has demonstrated proof of concept, safety and feasibility of the PEPPER safety system in MDI participants with T1D. The results suggest that a 6-week intervention with the PEPPER safety system and CGM has benefit in improving glycaemic control by reducing %time in clinically significant hypoglycaemia ($<3.0\text{mmol/l}$) and increasing %time in target ($3.9\text{--}10\text{mmol/l}$).

Our study is limited by small numbers and a short follow-up period, but the population and study design are comparable with previous reports for a feasibility study. Additionally, the feasibility study is not designed to show superiority. The results are encouraging and the overall system has been shown to be safe for use. However, without a control group, it is difficult to determine how much of the improvement was due to the safety system and how much to the prolonged CGM use.

The baseline data was derived from weeks 1 and 2 (with standard safety system), and compared to endpoint (with PEPPER system). Although no significance was observed in the primary endpoint, the International Hypoglycaemia Study Group [21] recommend that $<3.0\text{mmol/l}$ is a low enough but safe value to report ‘clinically relevant’ hypoglycaemia in clinical trials. People with T1D who are unaware of their hypoglycaemia at $<3.0\text{mmol/l}$ have a four-fold increased risk of severe hypoglycaemia [22]. This study was designed before this recommendation was published and had originally defined the level of hypoglycaemia at $<3.9\text{mmol/l}$.

The reduction in total number of alerts decreased as the study progressed, correlating with the improved glycaemic control with continued use of the PEPPER safety system. One limitation in this analysis includes the alert threshold being altered by participants due to “alarm fatigue”. A suggestion from several users was to include a vibration feature, which is to be incorporated into the system. It is also difficult to establish whether the handset had been switched off by the participants, and therefore if the alarm/alert had been acted upon.

Signal loss between the CGM sensor and the PEPPER handset was a consistent issue amongst most participants. Participants found that the handset and CGM could only connect within a 5-metre range. Data loss was addressed during the course of the study and is currently a main focus for improvement within the system.

During the course of the study, changes to insulin regime were made by clinicians to ensure participant safety. However, no significant changes to basal insulin dosing was found between run-in and endpoint to account for the significant reduction in hypoglycaemia.

All participants using the PEPPER system expressed a wish to continue using the system in to Phase 2 of the study. However, participants did experience and reported alarm fatigue on a regular basis. For this reason, alterations have been made to new feature releases, which include a vibration feature (instead of sound) and to downgrade hyperglycaemia alarms to alerts.

As only MDI participants were assessed in this feasibility study, the other module components (ie. the Dynamic Insulin Constraint and Low-glucose suspend modules) could not be tested. Further work with pump participants and in the form of a powered, randomised cross-over trial is planned to assess whether the complete PEPPER system, integrated with the case-based reasoning component, is superior to standard safety system and bolus calculator.

5 Conclusion

In conclusion, the PEPPER safety system is acceptable, safe and maintains improved glycaemic control in a small pilot population within an out-of-clinic environment. Despite being a short study, significant reduction in percentage time in hypoglycaemia with increase in time in target was observed. These results are promising for the day-to-day use of PEPPER for self-management of T1D.

Appendix A: Glucose Forecasting Algorithm

The glucose forecasting employed by three of the Safety System modules (i.e., predicted alerts; predictive low-glucose insulin suspend; and carbohydrate recommender) uses a compartmental model of glucose-

insulin dynamics composed by the minimal model of glucose-insulin regulation [23], the Hovorka's insulin absorption and glucose absorption models [24].

The algorithm forecasts glucose levels 30 minutes ahead by evaluating 30 times a discretised version (Euler method with 1-minute integration step) of the aforementioned composite minimal model, and detailed in [25]. In addition, every time (k) a new CGM value is received (e.g. every 5minutes), the states of the composite model are updated as follows. First, the model is simulated over the time window [k-1, k] (e.g. 5minutes) to obtain an estimate of the model states, i.e., rate of glucose appearance (R_a), plasma insulin concentration (I_p), plasma glucose concentration (G). Then, the deconvolution technique described by Herrero et al. [26] is used to obtain a second estimate of the rate of glucose appearance (\hat{R}_a). Subsequently, the current model's R_a state is updated by means of a weighted averaged between the model-estimated and the corresponding deconvoluted-estimate,

$$R_a := Q \cdot \hat{R}_a + (1 - Q) \cdot R_a, \quad (6)$$

where Q is a tuning factor, such as $Q \in [0,1]$.

Similarly, the current model's glucose concentration (G) is updated by means of a weighted average between the model-estimated and measured glucose values,

$$G := Q \cdot \text{CGM} + (1 - Q) \cdot G. \quad (7)$$

This averaging strategy can be seen as a way to decide how much trust is put on the measurements and how much on the model estimation. In this work, a $Q=0.6$ was employed. Figure 6 shows a graphical representation of the described glucose forecasting algorithm.




Figure 6. Block diagram corresponding to the proposed glucose forecasting algorithm. The whole diagram is executed every time a glucose value (CGM) is received. Then, the model represented by the physiological model represented by the green blocks is simulated over a 30-minute horizon to obtain the forecasted glucose.

In addition to the standard inputs (insulin and carbohydrates), the employed forecasting algorithm allows for the additional inputs of meal absorption information (slow, medium, fast) and physical exercise information (none, yes) to enhance prediction accuracy. Meal absorption information is accounted by changing the time-to-maximum glucose appearance parameter ($t_{\max G}$) of the meal absorption model (e.g. 45, 55, 90 minutes), while exercise is accounted by increasing the insulin sensitivity (SI) parameter by 30% over the exercise duration.

Parameters of the endogenous glucose-insulin (SI, V, and p_2) are individualized using retrospective clinical data from the studied individual, including CGM measurements, carbohydrate estimations and bolus insulin. A standard least-square parameter estimation technique aiming at minimising the forecasted glucose root mean square error was employed for this purpose. The remaining model parameters are fixed to mean population values.

The proposed algorithm has shown superior performance on retrospective clinical data from 10 adult subjects, when compared against a baseline glucose forecasting algorithm [27]. Root mean square errors expressed as mean \pm std in mmol/l were: 1.6 \pm 0.5 vs. 1.4 \pm 0.3 [28].

6 References

1. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. *The Lancet*, 383(9911), 69–82.
2. Facchinetti, A. (2016). Continuous Glucose Monitoring Sensors: Past, Present and Future Algorithmic Challenges. *Sensors*, 16(12), 2093–12.
3. Forlenza, G. P., Li, Z., Buckingham, B. A., Pinski, J. E., Cengiz, E., Wadwa, R. P., et al. (2018). Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. *Diabetes Care*, 41(10), 2155–2161.
4. Kovatchev, B. (2018). Automated closed-loop control of diabetes: the artificial pancreas. *Bioelectronic Medicine*, 4(14).
5. Klonoff, D. C. (2012). The Current Status of Bolus Calculator Decision-Support Software. *Journal of Diabetes Science and Technology*, 6(5), 990–994.
6. Yeh HC(1), Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. *Ann Intern Med*. 2012. 4;157(5):336-47.
7. Ramkissoon, C. M., Aufderheide, B., Bequette, B. W., & Vehi, J. (2017). A Review of Safety and Hazards Associated with the Artificial Pancreas. *IEEE Reviews in Biomedical Engineering*, 10, 44–62.

8. Buckingham, B., Cobry, E., Clinton, P., Gage, V., Caswell, K., Kunselman, E., et al. (2009). Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension. *Diabetes Technology & Therapeutics*, 11(2), 93–97.
9. Turksoy, K., Kilkus, J., Hajizadeh, I., Samadi, S., Feng, J., Sevil, M., et al. (2016). Hypoglycemia Detection and Carbohydrate Suggestion in an Artificial Pancreas. *Journal of Diabetes Science and Technology*, 10(6), 1236–1244.
10. Beneyto, A., Bertachi, A., Bondia, J., & Vehi, J. (2018). A New Blood Glucose Control Scheme for Unannounced Exercise in Type 1 Diabetic Subjects. *IEEE Transactions on Control Systems Technology*, PP(99), 1–8.
11. Bequette, B. W. (2014). Fault Detection and Safety in Closed-Loop Artificial Pancreas Systems. *Journal of Diabetes Science and Technology*, 8(6), 1204–1214.
12. Herrero, P., López, B., & Martin, C. (2016). Pepper: Patient empowerment through predictive personalised decision support. In *ECAI Workshop on Artificial Intelligence for Diabetes* (pp. 8-9).
13. Herrero, P., Pesl, P., Reddy, M., Oliver, N., Georgiou, P., & Toumazou, C. (2015). Advanced Insulin Bolus Advisor Based on Run-To-Run Control and Case-Based Reasoning. *IEEE Journal of Biomedical and Health Informatics*, 19(3), 1087–1096.
14. Torrent-Fontbona, F., & Ibanez, B. L. (2018). Personalised Adaptive CBR Bolus Recommender System for Type 1 Diabetes. *IEEE Journal of Biomedical and Health Informatics*, PP(99), 1–1.
15. Omer, T. (2016). Empowered citizen “health hackers” who are not waiting. *BMC Medicine*, 1–3.
16. Man, C. D., Camilleri, M., & Cobelli, C. (2006). A System Model of Oral Glucose Absorption: Validation on Gold Standard Data. *IEEE Transactions on Biomedical Engineering*, 53(12), 2472–2478.
17. Walsh, J., Roberts, R., Varma, C., Bailey, T. Using Insulin: Everything You Need for Success with Insulin. Torrey Pines Press. 2003.
18. F. Gao, Y. Wang, and F. J. Doyle, “Survey on iterative learning control, repetitive control, and run-to-run control,” *J. Process Control*, vol. 19, no. 10, pp. 1589–1600, 2009.

19. Schmidt, S., & Nørgaard, K. (2014). Bolus Calculators. *Journal of Diabetes Science and Technology*, 8(5), 1035–1041.
20. Moore, R. E., Kearfott, R. B., & Cloud, M. J. (2009). *Introduction to interval analysis* (Vol. 110). Siam.
21. International Hypoglycaemia Study Group. (2016). Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dl) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Table 1. *Diabetes Care*, 40(1), 155–157.
22. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycemia awareness in patients with long-duration insulindependent diabetes. *Lancet* 1994;344:283:287
23. Cobelli, C., Dalla Man, C., Toffolo, G., Basu, R., Vella, A., & Rizza, R. (2014). The Oral Minimal Model Method. *Diabetes*, 63(4), 1203–1213.
24. Hovorka, R., Canonico, V., Chassin, L. J., Haueter, U., Massi-Benedetti, M., Federici, M. O., et al. (2004). Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. *Physiological Measurement*, 25(4), 905–920.
25. Herrero, P., Calm, R., Vehí, J., Armengol, J., Georgiou, P., Oliver, N., & Tomazou, C. (2012). Robust fault detection system for insulin pump therapy using continuous glucose monitoring. *Journal of diabetes science and technology*, 6(5), 1131-1141.
26. Herrero, P., Bondia, J., Palerm, C. C., Georgiou, P., Oliver, N., & Toumazou, C. (2012). A Simple Robust Method for Estimating the Glucose Rate of Appearance from Mixed Meals. *Journal of Diabetes Science and Technology*, 6(1), 153–162.
27. C. Zhao, E. Dassau, L. Jovanovic, H. C. Zisser, F. J. Doyle III, and D. E. Seborg, “Predicting subcutaneous glucose concentration using a latentvariable- based statistical method for type 1 diabetes mellitus,” *Journal of diabetes science and technology*, vol. 6, no. 3, pp. 617–633, 2012.
28. Liu, C., Vehí, J., Oliver, N. Georgiou, P. Enhancing Blood Glucose Prediction with Meal Absorption and Physical Exercise Information. www.arXiv.org/